Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Protagonist Therapeutics Announces Amendment of Agreement with Janssen Biotech for the Continued Development and Commercialization of IL-23 Antagonists

firstwordpharmaJuly 29, 2021

Tag: Protagonist , Janssen Biotech , IL-23 Antagonists

PharmaSources Customer Service